Advertisement

Heterogeneity of tumor cells and metastases in breast cancer patients: cause or consequence?

  • Darko Zdravkovic
  • Dejan Nikolic
  • Marija Zdravkovic
Letter to the Editor
  • 163 Downloads

First of all, we would like to congratulate Sopik and colleague for their article [1] in which they tried to find out a relationship between tumor size, nodal status, and distant metastases. In this very comprehensive and detailed article, the authors concluded that the relationship between tumor size, lymph node status, and distant metastases in patients with invasive breast cancer is not linear. However, we would like to highlight our observation regarding this very important topic.

It is well known that the metastatic process is a multistep process, involving multiple genetic alterations affecting both tumor cells and the surrounding stroma, allowing spreading of metastases at distant sites. Tumor metastasis could be explained by two different models: linear progression model and parallel progression model, and this article is based on the first one. We could not neglect the fact that the release of tumor cells may happen also at early stages of the disease. Many studies confirmed that about 30–40% of patients in early stage of the disease may present occult metastasis derived from circulating tumor cells (CTCs). Contrary, data from preclinical animal studies have shown that less than 0.02% of circulating tumor cells can survive and have the capability to form metastatic lesion [2]. It is obvious that the heterogeneity of tumor cells rises during the tumors growth. We agree with authors that a smaller proportion of cells accessible to the vascular or lymphatic system in larger tumors because of lack of stable blood supply and further tumor necrosis. Undoubtedly that the tumor size is clinically and radiologically initial predictor of metastasis and prognosis, but heterogeneity of tumor cells in terms of genetic alterations and the status of host’s immune system is more predictable factor regarding metastases in breast cancer patients. Detailed histopathology and immunohistochemistry of primary tumor and affected lymph nodes or metastatic lesion could give precise information and determine further diagnostic procedures and therapy as well as prognosis [3].

Notes

Acknowledgements

The authors have not received any grants.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article complies with the ethical rules applicable for this journal.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Sopik V, Narod SA (2018) The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat 170(3):647–656CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kimbung S, Loman N, Hedenfalk I (2015) Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol 35:85–95CrossRefPubMedGoogle Scholar
  3. 3.
    Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M, Rydén L (2013) Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up. Breast Cancer Res Treat 140(1):93–104CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University Medical CenterBelgradeSerbia
  2. 2.Faculty of MedicineUniversity of BelgradeBelgradeSerbia

Personalised recommendations